The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. Issue 4 (25th May 2021)

• Record Type: Journal Article
• Authors: Ge, Yongpeng; Li, Sizhao; Chen, Fang; He, Linrong; Li, Chunjia; Lu, Xin; Wang, Guochun
• Is Part Of: Dermatologic therapy. Volume 34:Issue 4(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-25
• Subjects: calcinosis -- dermatomyositis -- idiopathic inflammatory myopathies -- infliximab -- skin lesion; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14976
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Anti‐TNF treatment may be useful for patients with idiopathic inflammatory myopathies (IIMs). The purpose of this study is to assess the efficacy of infliximab (IFX) in the management of IIMs. Two databases (ie, PubMed and China National Knowledge Infrastructure) were searched up to Nov 2020 for studies investigating skin lesions and muscular weakness in patients with IIMs treated with IFX. A total of 18 studies were included. One hundred and eighteen patients were identified, including 58 adult patients and 60 patients with juvenile dermatomyositis (JDM) treated with IFX. Among these patients, 110 (93%) patients with refractory cases. In addition to glucocorticoids, patients from 15/18 studies received immunosuppressant agents (ISAs) concomitantly with IFX, among which methotrexate (MTX) was most common. After treatment with IFX, skin lesions and muscle strength were improved in 67% of patients with DM and 75% of patients with JDM, respectively. Skin calcinosis was improved in 21/34 (62%) of patients with JDM. Only 55% (12/22) of patients with polymyositis exhibited improvements in muscle strength. Lastly, 40% (42/104) of patients reported adverse events. Current evidence appears to support the use of IFX in some patients with refractory IIMs, especially those with JDM. The most common adverse reaction was infection. Large, randomized‐controlled studies should be carried out to confirm these findings.